Sofinnova Investments, Inc. Jounce Therapeutics, Inc. Transaction History

Sofinnova Investments, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $1.4 Million - $3.83 Million	-499,291 Reduced 33.71%	981,928 $2.98 Million
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $610,363 - $867,305	-101,558 Reduced 6.42%	1,481,219 $10.1 Million
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $6.72 Million - $9.11 Million	945,430 Added 148.34%	1,582,777 $13.2 Million
Q3 2021 Nov 15, 2021	BUY	$5.04 - $8.73 $63,458 - $109,919	12,591 Added 2.02%	637,347 $4.74 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $743,105 - $1.2 Million	112,934 Added 22.07%	624,756 $4.25 Million
Q1 2021 May 14, 2021	SELL	$6.73 - $13.87 $2.78 Million - $5.73 Million	-413,458 Reduced 44.68%	511,822 $5.26 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $5.89 Million - $9.56 Million	925,280 New	925,280 $6.48 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.